Valion Bio, Inc. Common Stock (VBIO) Stock Price

VBIOStock

$0.16

Market Cap$660,050.181

P/E—

PEG Ratio—

Div yield—

Beta3.57

VBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (4W)-45.37%

VGM Score47.13

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-14.77%

Cash Flow / Share (Quarterly)$-4.07

Price vs S&P 500 (YTD)-90.84%

Gross Margin (TTM)-58.09%

Net Profit Margin (TTM)-1557.26%

EPS (TTM)$-8.23

10-Day Avg Trading Volume50.30M

EPS Excl Extra (TTM)$-8.23

Revenue Growth (5Y)13.18%

EPS (Annual)$-19.68

ROI (Annual)-223.08%

Gross Margin (Annual)0.26%

Net Profit Margin (5Y Avg)-614.40%

Cash / Share (Quarterly)$2.51

Revenue Growth QoQ (YoY)15.87%

ROA (Last FY)-201.46%

Revenue Growth TTM (YoY)81.20%

EBITD / Share (TTM)$-6.81

ROE (5Y Avg)-194.14%

Operating Margin (TTM)-1548.96%

Cash Flow / Share (Annual)$-3.00

P/B Ratio0.05x

Net Income / Employee (Annual)$-108,700

Net Interest Coverage (TTM)-5.11x

ROA (TTM)-77.00%

EPS Incl Extra (Annual)$-19.68

Current Ratio (Annual)20.13x

Quick Ratio (Quarterly)2.76x

3-Month Avg Trading Volume6.60M

Revenue / Employee (TTM)$9,300

P/S Ratio (Annual)1.16x

Asset Turnover (Annual)0.28x

52-Week High$1.30

Operating Margin (5Y Avg)-584.97%

EPS Excl Extra (Annual)$-19.68

Quick Ratio (Annual)19.60x

13-Week Price Return-81.11%

Total Debt / Equity (Annual)0.27x

Current Ratio (Quarterly)3.31x

Enterprise Value$4.22M

Revenue / Share Growth (5Y)-10.27%

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$15,000

Inventory Turnover (Annual)1.45x

Pretax Margin (Annual)-725.00%

Cash / Share (Annual)$5.01

3-Month Return Std Dev155.39%

Gross Margin (5Y Avg)2.21%

Net Income / Employee (TTM)$-170,700

ROE (Last FY)-223.08%

Net Interest Coverage (Annual)-17.53x

EPS Basic Excl Extra (Annual)$-19.68

Receivables Turnover (TTM)34.43x

Total Debt / Equity (Quarterly)0.37x

EPS Incl Extra (TTM)$-8.23

Receivables Turnover (Annual)6.42x

ROI (TTM)-82.71%

P/S Ratio (TTM)1.87x

Pretax Margin (5Y Avg)-614.40%

Revenue / Share (Annual)$2.71

Year-to-Date Return-83.56%

5-Day Price Return3.36%

EPS Normalized (Annual)$-19.68

ROA (5Y Avg)-165.61%

Net Profit Margin (Annual)-725.00%

Month-to-Date Return-46.45%

EBITD / Share (Annual)$-19.69

Operating Margin (Annual)-725.77%

LT Debt / Equity (Annual)0.27x

ROI (5Y Avg)-194.14%

LT Debt / Equity (Quarterly)0.37x

EPS Basic Excl Extra (TTM)$-8.23

P/B Ratio (Annual)1.34x

Inventory Turnover (TTM)2.07x

Pretax Margin (TTM)-1557.26%

Book Value / Share (Annual)$26.33

Price vs S&P 500 (13W)-83.90%

Beta3.57x

Revenue / Share (TTM)$0.36

ROE (TTM)-97.34%

52-Week Low$0.11

gGradeB

mGradeD

vgmGradeC

VBIO Earnings Surprise History

Q4 22-391.00est. -527.00

Q1 23-187.00est. -187.00

Q2 23-119.00est. -136.00

Q3 23-25.16est. -119.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
VBIOValion Bio, Inc. Common Stock	—	B	D	$0.16
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Valion Bio, Inc. Common Stock

Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.